INTRODUCTION {#S0001}
============

MDS or Myelodysplastic syndrome is a group of blood and marrow disorders. Stem cells do not mature in MDS and the number of immature and dysplastic cells increase.^[@CIT0001]--[@CIT0004]^ In most cases, the disease would progress gradually. So cytopenia would become worse and move toward bone marrow failure.

Approximately 80-90% of MDS cases occur among patients older than 60.^[@CIT0005]^ Each year, 1200 new cases of MDS are diagnosed in US.^[@CIT0001]--[@CIT0004],\ [@CIT0006]^

MDS patients' morbidity and mortality associated with low blood cell counts that may be in the form of anemia, bleeding arising from thrombocytopenia and infection arising from decrease in white blood cell counts^[@CIT0007]^ and eventually patient would enter acute leukemia phase. In addition to this primary type of MDS, in practice we observe some patients who are similar to primary MDS patients in terms of laboratory, clinical and morphology of blood and marrow, but a reason for this type of disease would be mentioned, so the use of "secondary MDS" term may become applicable. Typically, secondary MDS is the result of DNA damage from chemotherapy^[@CIT0005],\ [@CIT0008]--[@CIT0011]^ or RT^[@CIT0012]^ to blood cells that specially occurs in the combination of radiation and Alkylating factors such as Busulfan, procarbazine, Nitrous urate that usually happens after a period of 5-7 years of this disease or for drugs such as topoisomerase inhibitors from MDS II during a 2 year period. So, secondary MDS may be a delaying complication of cancer treatment. MDS in aplastic anemia cases occur after receiving immune suppressive drugs during follow up period. Peripheral blood morphology, BMA, BMB and cytogenetic test would be conducted apart from CBC diff and Plt count for MDS diagnosis.^[@CIT0004],\ [@CIT0013],\ [@CIT0014]^ Symptoms that are defined as MDS in peripheral blood and marrow are as follows: Peripheral Blood Cytopenia, ineffective haematopeiesis, dysgranulopoiesis (hypogranulation, pseudo pelger huet), dysmegakaryopoiesis (hyposegmented Megakaryocyte nucleus), dyserythropoiesis^[@CIT0015]^ and the increase of Blast counts. Of course dysplasia that involves all 3 cell categories was observed in marrow. In Am J Hematology study that was published in 1992, the relation between malignancy and MDS has been reported and some cases of diagnosis have been occurred prior to malignancy and some cases have been the same time or after diagnosis.^[@CIT0016]^ MDS diagnosis was also accomplished on the basis of available criteria.

CASE STUDY {#S0002}
==========

Based on an investigation during 2007-2012, patients diagnosed as MDS based on MDS criteria, we have encountered with patients who can be involved in secondary MDS. The reason for such patients' referral was cytopenia and they were diagnosed as MDS in marrow study, but most of them were young and since the beginning, there has been suspicion to systematic diseases, auto immune diseases^[@CIT0017]^ or malignancy as the cause of cytopenia and MDS. Apart from supportive cares and treatments for MDS, it has been considered to search for malignancy or systematic diseases as a cause of MDS. However at the beginning we did not come into any specific conclusion. Most patients required blood injection in order to keep the level of appropriate Hb for ordinary activities.

Age and sex specifications of such patients are identified in [Table 1](#T0001){ref-type="table"}.

###### 

Patients' Age and Sex and Type of Malignancy in This Case Study

  No.   Age   Sex      Interval before diagnosis (month)   Malignancy
  ----- ----- -------- ----------------------------------- ----------------
  1     27    FEMALE   7                                   Breast Cancer
  2     45    MALE     9                                   Colon Cancer
  3     40    FEMALE   12                                  Colon Cancer
  4     28    FEMALE   6                                   HD
  5     39    FEMALE   4                                   HD
  6     52    MALE     20                                  Gastric Cancer

Presentation and characteristics of these patients are as below:

The first patients was a 27 year old female who has been referred because of Anemia and Leukopenia and during follow up due to Anemia continuity and refractory anemia, she underwent BMA and BMB and had MDS criteria ([Figure 1](#F0001){ref-type="fig"}).

![Patients was a 27 year old female\
Dyserythropoiesis, Dysgranolopoiesis (pseudo pelger huet raw)](IJHOSCR-7-030-g001){#F0001}

Besides repeated blood injection along with supportive and therapeutic measures she had been followed up and during a 7 month period, she had a surgery because of Breast mass and she was diagnosed as breast cancer. Patient underwent chemotherapy and Anemia and Cytopenia has been completely resolved after the completion of treatment.

The second patient was a 49 year old man who was referred to clinic because of Macrocytic Anemia and low Retic count and he underwent BMA and BMB because of Anemia continuity and has diagnosed as MDS in BMA ([Figure 2A](#F0002){ref-type="fig"}, [2B](#F0003){ref-type="fig"}).

![A 49 year old man with dysmegakaryopoiesis\
Unilobule megakaryocytic](IJHOSCR-7-030-g002){#F0002}

![49 year old man who was referred to clinic because of Macrocytic Anemia\
Dyserythropoiesis, Dysgranolopoiesis](IJHOSCR-7-030-g003){#F0003}

During follow up period, patient required blood injection once each 15 days, so thalidomide was started for him. He had frequent infections because of leukopenia and had a history of hospitalization. During follow up period and after 1.5 months of thalidomide initiation and 9 months later, he was affected by colon cancer and had no problem in CBC diff. after treatment of colon cancer.

The third patient was a 40 year old female due to refractory anemia and leucopenia. She underwent BMA and BMB and had MDS criteria including dyserithropoies and dysgranlopoiesis ([Figure 3](#F0004){ref-type="fig"}) who has been diagnosed by colon cancer during a12 months follow up period.

![The third patient was a 40 year old female\
Dyserythropoiesis](IJHOSCR-7-030-g004){#F0004}

The fourth patient was a 28 year old female who has been referred because of Macrocystic Anemia, thrombocytopenia and low Retic counts. During 6 months follow up interval, patient affected by neck mass and she was diagnosed as Hodgkin lymphoma. However she no need to blood transfusion but MDS criteria ([Figure 4](#F0005){ref-type="fig"}) disappeared after treatment of oncology disease.

![A 28 year old female\
Dyserythropoiesis](IJHOSCR-7-030-g005){#F0005}

The fifth patient was a 39 year old female who was referred because of severe Anemia and Cytopenia and she was diagnosed as MDS in BMA ([Figure 5](#F0006){ref-type="fig"}). During a 4 month follow up period, she had a mass in supraclavicular area and after neck mass resection; she was diagnosed as Hodgkin\'s lymphoma and patients required blood injection and antibiotics for infection treatment. After the treatment of fourth and fifth patients, blood disorders are totally resolved. In next BMA review, Myelofibrosis or RS (reed-sternberg cell) wasn\'t seen.

![39 year old female](IJHOSCR-7-030-g006){#F0006}

The sixth patient was a 52 year old male who had referred to clinic because of pancytopenia including thrombocytopenia and anemia and leukopenia and demonstrated MDS criteria in BMA. For this patient initiated nutrition drug but no needed to transfusion.

During a 20 month follow up period, no considerable progression in MDS observed and he underwent treatment because of gastric cancer and after the end of treatment, his blood disorders totally resolved.

DISCUSSION {#S0003}
==========

Often we observe Cytopenia in peripheral blood when coping with patients who have malignancy and anemia sounds very outstanding on this regard. Malignant cells may produce TNF and cytokine which may lead to the decrease of red cells production and long life. Also cytopenia may arise from chemotherapy, radiotherapy or infiltration of marrow by malignant cells. This case study represents that we can consider MDS as a paraneoplastic issue that is developed several months prior to cancer presentation.
